17 results about "Teprenone" patented technology

The embodiment of the invention discloses a teprenone-containing composition, a skin care product and application. The teprenone-containing composition and the skin care product can promote the expression of CD44. The composition containing the teprenone is prepared from the teprenone and acetyl tripeptide-30 citrulline, and the mass ratio of the teprenone to the acetyl tripeptide-30 citrulline is 50 to (15 to 25).

The invention discloses a synthesis method of teprenone, which comprises the following steps: dissolving farnesyl acetone in a solvent, and reacting with a Grignard reagent at low temperature to obtain geranyl linalool; the method comprises the following steps: mixing geranyl linalool, alkyl acetoacetate and an organic aluminum catalyst, reacting under a heating condition, adding a dilute acid solution and an organic extraction solvent into the reacted mixed solution, extracting, separating an organic phase to obtain a teprenone crude product, and carrying out reduced pressure distillation purification to obtain teprenone, the yield and the purity of the teprenone in industrial production are improved.

The invention belongs to the technical field of biological medicines, and particularly relates to amniotic mesenchymal stem cells for treating gonitis as well as a preparation method and application of the amniotic mesenchymal stem cells. The preparation method of the amniotic mesenchymal stem cells comprises the following specific steps: (1) separating to obtain amniotic tissues; (2) digesting, filtering and centrifuging the amniotic membrane tissues to obtain cell precipitates; (3) precipitating and resuspending the cells, inoculating the cells to a culture medium for culture, digesting, centrifuging, and discarding supernatant to obtain P0-generation amniotic mesenchymal stem cells; and (4) inoculating the P0-generation amniotic mesenchymal stem cells into a culture medium for subculture to obtain the amniotic mesenchymal stem cells. By adding teprenone and schaftoside into the basic culture medium, the cell dryness of the amniotic mesenchymal stem cells can be maintained, and the osteogenic differentiation capability of the amniotic mesenchymal stem cells is improved, so that the gonitis is effectively treated. Meanwhile, fetal calf serum is not added into the basic culture medium, so that the safety of clinical application is improved.

The present application relates to the field of skin care products, and discloses a whitening and anti-aging composition for skin care products and application thereof, and an essence oil and a preparation method thereof. The whitening and anti-aging composition for skin care products contains an active substance combination and a compound essential oil and plant oil combination; the active substance combination contains glabridin, 4-butyl resorcinol, undecylenoyl phenylalanine, natural bisabalol, ascorbic acid tetraisopalmitate and teprenone; the compound essential oil and plant oil combination contains Damascus rose essential oil, magnolia essential oil, frankincense essential oil, Roman chamomile essential oil, carrot seed essential oil, passion fruit seed oil, red wolfberry seed oil, rose fruit oil and sea buckthorn fruit oil. The skin care product prepared from the whitening and anti-aging composition has a more moderate and efficient transdermal absorption rate, and has excellent anti-photoaging effect and whitening and freckle-removing effect.

A method for the industrial production of teprenone and its application. The present invention belongs to the field of teprenone synthesis. The purpose of the present invention is to solve the technical problems of the existing teprenone synthesis method, which has a long route, many side reactions, and requires the use of special reagents. The method of the present invention comprises the following steps: first, farnesene is reacted with acetoacetate in the presence of a catalyst to obtain farnesene ketone ester, which is then decarboxylated to produce farnesene acetone, and then subjected to a reduction reaction, a halogenation reaction, and a Wittig reaction to obtain teprenone. The method avoids the shortcomings of existing processes, has fewer conversion steps in the synthesis route, and produces teprenone with high yield and purity, making it suitable for industrial production. The teprenone of the present invention is used as a drug for treating gastric diseases.

The invention belongs to the field of organic synthesis, and particularly relates to a preparation method of teprenone. The invention aims to solve the technical problems that the existing teprenone synthesis route is complicated, the stereo configuration of a synthesis precursor is difficult to control and the like. According to the method, alpha-farnesene, beta-farnesene, farnesol and nerolidol which are sourced from microbial fermentation are used for preparing a farnesyl acetone crude product, and then high-purity all-trans (5E, 9E)-farnesyl acetone is obtained through rectification, or all-trans (5E, 9E)-farnesyl acetone is directly synthesized from beta-farnesene and farnesol. Therefore, commercial teprenone with qualified quality can be obtained through subsequent reaction.

The present invention belongs to the technical field of chemical detection, and specifically relates to a method for detecting teprenone isomers. Teprenone is a digestive system drug for acid suppression and gastric mucosal protection, and is a mixture of isomers, with the all-trans structure playing the main pharmacodynamic role; therefore, developing a simple and practical method that can effectively separate and detect the two isomers of teprenone, mono-cis (5Z, 9E, 13E) and all-trans (5E, 9E, 13E), is of great significance for conducting research on the synthesis of all-trans teprenone and production quality control. The invention discloses a method for detecting teprenone isomers, and high performance liquid chromatography is used to detect two isomers of teprenone, the chromatographic column is a chiral column, CHIRALPAK IB (4.6*250mm, 5μm); the flow rate is 0.7-0.9mL / min; the column temperature is 20-30℃; the injection volume is 10-50μL; the wavelength is 210-220nm; the mobile phase is n-hexane: n-butanol: anhydrous ethanol = (80-75): (15-20): 5; the elution procedure is isocratic elution; the elution times of the two isomers of teprenone, the all-trans and mono-cis, are 8.270min and 9.113min respectively, the separation degree is 2.68, the baseline is stable, and the main peak shape in the test solution is good. Through methodological verification, the method can be applied to the separation and content determination of the two isomers of teprenone, the mono-cis and all-trans, in teprenone bulk drugs or teprenone capsules.

The invention relates to the field of cosmetic preparations, in particular to cream containing teprenone and having a red-removing effect and a preparation method of the cream. The cream is prepared from the following raw materials in parts by weight: 50 to 80 parts of water, 6 to 15 parts of a polyhydric alcohol humectant, 3 to 6 parts of an emulsifier, 10 to 25 parts of an emollient, 0.1 to 0.4 part of carbomer, 0.1 to 0.4 part of a pH regulator, 0.8 to 1.5 parts of a preservative and 0.05 to 1 part of teprenone-citric acid monoester. Through esterification modification of hydroxyl or amino sites of teprenone, the stability and transdermal absorption capacity of teprenone in a cream system are improved, so that the soothing, repairing and red-removing effects are enhanced. The prepared cream is free of layering and peculiar smell after being stored at 40 DEG C for 3 months, has good appearance and application stability, and is suitable for daily nursing of sensitive or reddish skin.

The embodiment of the invention provides a composition for promoting cadherin expression, a skin care substance and application. The composition and the skin care substance can be used for promoting DSG1 expression. The composition with the function of promoting cadherin expression comprises teprenone, ceprenone, and ceprenone, and a compound represented by formula (1); wherein formula (1):

The invention discloses application of teprenone in preparation of a medicine for treating children's premature senility (HGPS), and relates to the technical field of biological medicine. Experiments show that teprenone can significantly improve HGPS senescence-related phenotypes: in HGPS model monkey skin fibroblasts, the expression of nuclear fiber layer protein Lamin B1 is up-regulated, the activity of beta-galactosidase is reduced, and the expression of senescence-related secretion phenotype factors is inhibited; in an LmnaG608G mutant HGPS mouse model, the life time is prolonged, Progerin protein expression is down-regulated, phenotypes such as weight loss, skin fibrosis, liver fibrosis and vascular smooth muscle cell deficiency are improved, and the thickness of subcutaneous adipose tissue is increased. As a batch clinical drug, teprenone has a clear safety characteristic and a low side effect risk, existing clinical data can be fully utilized when teprenone is developed as an HGPS treatment drug, the research and development period is shortened, and the teprenone has an important conversion medical value.

The invention belongs to the field of organic chemistry, and particularly relates to a preparation method of gamma, delta-unsaturated ketone by adopting a continuous flow process. According to the present invention, the existing Karol rearrangement reaction is improved, and the gamma, delta-unsaturated ketone preparation method using the continuous flow process is provided, and is successfully used in the synthesis of farnesyl acetone and teprenone. The preparation method disclosed by the invention can be safely, rapidly and continuously carried out at high temperature and high pressure, greatly improves the reaction efficiency, reduces unnecessary heat energy loss, and is green, environment-friendly, economical and more suitable for industrial production.

The application discloses a complex of ursodeoxycholic acid or obeticholic acid and teprenone and application of the complex in preparation of a medicine for preventing and treating liver fibrosis. The combination of ursodeoxycholic acid or obeticholic acid and teprenone can significantly reduce the levels and contents of glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminase (AST) and hydroxyproline (Hyp) in model mice, thereby the effect of ursodeoxycholic acid or obeticholic acid in treating liver fibrosis can be enhanced. Therefore, the complex of ursodeoxycholic acid or obeticholic acid and teprenone has a potential for preventing and treating liver fibrosis, which is superior to ursodeoxycholic acid or obeticholic acid single component.

Embodiments of the present disclosure disclose a use of a composition in the preparation of a retinoic acid X receptor gamma activator, the composition comprising phytol, teprenone, and silybin. Embodiments of the present disclosure also disclose a use of the composition in the preparation of an extracellular matrix metalloproteinase inhibitor and an interleukin-6 inhibitor at a specific ratio.

The invention discloses a teprenone capsule degradation impurity detection method, which uses a mixed solvent composed of normal hexane, ethyl acetate and an additive as a developing solvent, and adopts thin layer chromatography to separate and detect teprenone degradation impurities. The additive is an acetone solution of benzoic acid; the specific detection method comprises the following steps: dissolving contents in the teprenone capsule in an organic solvent, filtering, taking filtrate to obtain a test solution, and diluting the test solution with the organic solvent to obtain a contrast solution; respectively dripping the test solution and the contrast solution on a thin-layer plate, and developing by adopting the developing solvent; and taking out the unfolded thin-layer plate, airing, spraying a color developing agent on the thin-layer plate, heating, and inspecting under ultraviolet light. According to the invention, the degradation impurities in the teprenone capsule are determined by thin layer chromatography, and are compared with a control solution, so that whether the degradation impurities in a test sample meet limit requirements or not can be clearly compared.

The invention belongs to the technical field of organic synthesis, and particularly relates to a synthesis method and application of teprenone, and the synthesis method of the teprenone comprises the following steps: carrying out reduction reaction, halogenation reaction, Witting reaction and oxidation reaction on farnesyl acetone to obtain the teprenone. The synthetic route is simple, the experimental steps are few, and the prepared teprenone is high in yield and high in purity. Besides, the teprenone disclosed by the invention is mainly used in the field of skin care with cosmetic efficacy, and in a fibroblast model, the teprenone can significantly up-regulate the expression quantity of telomerase, TRF2, CDK2, CBX5 / HP1, SERTAD3 and ELAVL1 genes, and has an anti-aging effect.

This disclosure relates in general to methods for treating, stabilizing, or reducing the severity or slowing the progression of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), using an inhibitor of tumor progression site 2 (TPL2) kinase, and pharmaceutical compositions including TPL2 kinase inhibitors used in such methods.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a teprenone emulsion and a preparation method thereof, the teprenone emulsion comprises teprenone, cyclodextrin, an oil phase, an emulsifier, a stabilizer, a preservative and water; comprising the following steps: S1, adding cyclodextrin into purified water, stirring to completely dissolve the cyclodextrin, then adding teprenone, controlling the clathration temperature, and stirring for clathration; s2, accurately weighing an emulsifier, a stabilizer and a preservative, dissolving in the solution obtained in S1, and heating; s3, accurately weighing the oil phase, uniformly stirring and heating; and S4, adding the oil-phase solution obtained in S3 into the water-phase solution obtained in S2, uniformly mixing, homogenizing by adopting a high-pressure homogenizer at set temperature and pressure, and cooling to room temperature to obtain the teprenone emulsion. The teprenone is prepared into an oil-in-water emulsion, and the teprenone is wrapped by cyclodextrin by adopting a cyclodextrin inclusion technology, so that direct contact between a medicine and an external environment is avoided, and the stability of the teprenone is improved.